Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Exclusion Criteria

• •Subject is pregnant, lactating, is planning to become pregnant during the study, or is less than one year postpartum.
• •Subject is a smoker within one year prior to Visit 1/Screening.
• •Subject has known history of secondary hyperhidrosis.
• •Subject has existence of neurological, psychiatric, endocrine, or other disease that can cause secondary hyperhidrosis or affect sweating.
• •Subject has known history of Sjögren's syndrome or Sicca syndrome.
• •Subject has used any of the following hyperhidrosis medications or therapies within the specified timeframe:
• •1. Iontophoresis to the palms within four weeks prior to baseline visit;
• •2. Botulinum toxin to the palms within one year prior to baseline visit;
• •3. Prior surgical procedures to the palms (e.g., sympathectomy, debulking of sweat glands);
• •4. Prior medical device treatment to the palms (approved or investigational);
• •5. Any treatments for hyperhidrosis within four weeks prior to baseline visit.
• •Subject is currently enrolled in an investigational drug or device study.
• •Subject has previously participated in a clinical study of dexmecamylamine or TC-5214.
• •Subject has used an investigational drug or investigational device treatment within 30 days prior to baseline.
• •Subject has a history of sensitivity to any of the ingredients in the study drugs.